Is GlaxoSmithKline plc’s 6% dividend yield safe?

The market seems to be suggesting that GlaxoSmithKline plc’s (LON: GSK) dividend will be cut.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Following the release of GlaxoSmithKline‘s (LSE: GSK) third-quarter figures last week, shares in the company have crumbled due to rising concerns about the company’s dividend payout. 

This isn’t the first time the company has faced such concerns. Several years ago the shares took a beating as the City proclaimed that falling earnings per share, a result of patent expirations, would force the company to slash its shareholder distribution. 

This cut never materialised. Instead, management promised to hold the payout at 80p per share until at least 2018. 

Unfortunately, it’s now looking increasingly likely that the firm will slash its payout next year. 

Turning the business around 

Over the past few years, Glaxo’s business has been through a rough patch. Luckily, the firm has been able to recover from its problems, and thanks to new treatments, as well as weak sterling, earnings have ticked higher. After earnings per share hit a low of 75p in 2015, this year the company is on track to earn 110p. 

EPS of 110p easily cover the 80p per share dividend payout. However, on a cash basis, the payout looks vulnerable. Indeed, for the first nine months of this year, the company produced just over £4bn in cash from operations and spent £1.5bn on capex, giving a free cash flow of £2.5bn before dividends. Dividends for the period amounted to £3bn leaving a gap of £500m. 

Going forward, the cash squeeze might get even tighter if the company chooses to pursue growth. Glaxo is eyeing potential acquisitions from Pfizer in the US and Merck in Germany to boost its consumer division.  The Pfizer business is estimated to be worth $14bn. 

Meanwhile, the firm is apparently preparing to buy out the 36.5% stake in its joint venture with Novartis for $10.3bn. These are some sizable figures, and Glaxo’s balance sheet can’t take on much more debt to fund acquisitions. So, it’s entirely reasonable to assume that the firm could cut its dividend by 50% or more to save a few billion a year and fund expansion. 

This is a delicate trade-off. On the one hand, a dividend cut will help reignite earnings growth. On the other hand, a reduction will make the stock less appealing to dividend hunters who are currently attracted to the near 6% dividend yield.  

To cut or not to cut 

In my view, Glaxo will reduce its dividend yield. Maintaining the payout at 80p per share has really taken its toll on the business as net debt has risen from £9bn to £14bn over the past six years. Shareholder equity (total assets minus total liabilities) has collapsed from £8bn to £1.1bn over the same period. If this trend continues, and growth remains sluggish, sooner or later the company will have to make some tough decisions.

I believe management should act before it is pushed. A 50% cut would reduce the payout to 40p per share, that’s still a yield of around 3% at current prices, which is only just below the market average. Yet it may be too low for some investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »